U.S. Unfractionated Heparin Market to Surpass US$ 501.5 Million by 2027

The U.S. Unfractionated Heparin Market, by Source (Porcine and Bovine), by Injection Type (IV Injection and Subcutaneous Injection), and by Disease Indication (Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism & Arterial Embolism), was valued at US$ 335.4 million in 2018 and is expected to exhibit a CAGR of 4.5% over the forecast period (2019 – 2027), as highlighted in a new report published by Coherent Market Insights.

Increasing prevalence of thromboembolic diseases, owing to the rising number of obese and older population in U.S. is expected to drive growth of the U.S. unfractionated heparin market over the forecast period. For instance, according to the Circulation Research Journal, a journal of the American Heart Association (AHA), in 2016, in the U.S., study estimates showed that age-stratified incidence was 143 per 100,000 among people of age 40 to 49 years, 200 per 100,000 among people of age 50 to 59 years, 391 per 100,000 among people of age 60 to 69 years, 727 per 100,000 among people of age 70 to 79 years, and 1,134 per 100,000 among people of age ≥80 years.

Major players are focusing on acquisitions to expand their product portfolio and presence in the market, which is expected to drive the market growth over the forecast period. For instance, in July 2016, Nichi-Iko Pharmaceutical Co., Ltd acquired Sagent Pharmaceuticals, Inc., a U.S.-based manufacturer of pharmaceutical injectable, valued at US$ 736 million. This acquisition enhanced Nichi-Iko’s presence in the U.S. market to commercialize its biosimilar product portfolio.

Browse 12 Market Data Tables and 10 Figures spread through 82 Pages and in-depth TOC on ‘U.S. Unfractionated Heparin Market’, by Source (Porcine and Bovine), by Injection Type (IV Injection and Subcutaneous Injection), and by Disease Indication (Venous Thromboembolism, Cardioversion of Atrial Fibrillation, and Pulmonary Embolism & Arterial Embolism) - Global Forecast to 2027.

To know the latest trends and insights prevalent in the U.S. unfractionated heparin market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-unfractionated-heparin-market-3187

The U.S. unfractionated heparin market is expected to exhibit growth over the forecast period, owing to increasing prevalence of thromboembolic diseases. For instance, according to the Circulation Research Journal, a journal of the American Heart Association, in 2016, the study reported that the incidence of venous thromboembolism (VTE) is higher as age increases in the U.S.

Moreover, favorable regulatory framework is also offering lucrative opportunity for growth of the market. For instance, in September 2019, the U.S. Food and Drug Administration (FDA) directed that all forms of imported heparin are subjected to compliance testing, in order to reduce risk of complication such as heparin induced thrombocytopenia and deaths associated with imported heparin.

Key Takeaways of the U.S. Unfractionated Heparin Market:

• The global U.S. unfractionated heparin market is expected to exhibit a CAGR of 4.5% over the forecast period, owing to increasing cases of thromboembolism in the U.S. and acquisition strategies by players in the U.S. unfractionated heparin market
• Among source, porcine segment held dominant position in the U.S. unfractionated heparin market in 2018, owing to the U.S. Food and Drug Administration (FDA) approval for sources used for manufacturing of heparin. For instance, the only commercially available source in U.S. for the heparin production is porcine, derived from porcine intestinal mucosa.
• Among injection type, IV injection segment held dominant position in the U.S. unfractionated heparin market in 2018, owing to rising mergers & acquisitions by market players. For instance, in September 2016, Baxter International Inc. acquired Claris Injectable, an India-based generic injectable pharmaceutical company. This acquisition helped Baxter to increase the production of injectable such as anesthesia and analgesics, anti-infective, renal and critical care products.
• Among disease indication, venous thromboembolism segment held dominant position in the U.S. unfractionated heparin market in 2018, owing to rising cases of thromboembolism. According to the data and statistics published by the National Center on Birth Defects and Developmental Disabilities, a part of Centers for Disease Control and Prevention in March 2019, venous thromboembolism (VTE) is the foremost cause of preventable hospital death in the U.S. Around 5.0% to 8.0% of the U.S. population has one of the several genetic risk factors. It is also known as inherited thrombophilias, wherein a genetic defect can be identified that increases the risk for thrombosis.
• Companies operating in the global U.S. unfractionated heparin market include Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., and Bayer AG